tirzepatide vs semaglutide weight loss trials vs Retatrutide: Which causes the most —and what happens to muscle? RWD study: Mounjaro more effective

The core machinery of this axis is the IP3R-GRP75-VDAC1 tripartite complex, where GRP75 (Szabadkai et al., 2006) acts as a linker protein that physically bridges the IP3R on the ER (Bartok et al., 2019) to the VDAC1 channel on the mitochondria (Rapizzi et al., 2002), funneling ions directly into the mitochondrial matrix (Szabadkai et al., 2006)

Pancreatic considerations: GLP-1 agonists increase pancreatic enzyme output

The STEP-1 trial demonstrated mean weight loss of 14.9% with semaglutide over 68 weeks, while the SURMOUNT-1 trial showed tirzepatide achieving 16-22.5% weight reduction over 72 weeks

More recently, NICE Technology Appraisal TA875 has supported the use of semaglutide 2.4 mg (Wegovy) within specific criteria, including a BMI of 35 kg/m or above (or lower in certain high-risk groups) with at least one weight-related comorbidity

A new survey from ZipHealth suggests that public opinion may be more supportive than many people realize